Evenity (Romosozumab) FDA Approval History

Evenity is the brand name for romosozumab-aqqg, a humanized monoclonal antibody that works by inhibiting sclerostin to promote bone formation. Unlike bisphosphonates, SERMs, and denosumab (Prolia/Xgeva), romosozumab represents a distinct anabolic class of osteoporosis therapy. This overview documents the drug's regulatory pathway through the FDA and the cardiovascular safety concerns that influenced its prescribing label. This resource is intended for regulatory context only and does not provide dosing information or replace the need for individual cardiovascular risk evaluation by the treating clinician.

The FDA approved Evenity (romosozumab-aqqg) on April 9, 2019, for osteoporosis treatment in postmenopausal women at high fracture risk, following an initial rejection tied to a cardiovascular safety signal. The approved label carries a boxed warning for myocardial infarction, stroke, and cardiovascular death, restricts use to a fixed course of 12 monthly doses, and contraindicates the drug in anyone with a myocardial infarction or stroke in the preceding year (FDA approval letter, BLA 761062, accessdata.fda.gov, 2019). Everything past this point involves tradeoffs the label does not fully resolve for an individual patient, which is why cardiovascular risk stratification before starting therapy matters more for this drug than for most osteoporosis treatments.

Why the FDA rejected it the first time

Amgen and UCB submitted the original Biologics License Application (BLA 761062) in 2016, built on the FRAME trial's fracture-reduction data. According to Amgen's and FDA's public account of the review, an FDA advisory committee voted against approval in 2017 after a comparator trial (ARCH, romosozumab versus alendronate) showed more cardiovascular events in the romosozumab arm than expected. The FDA issued a Complete Response Letter in 2017 requesting more safety analysis. The exact advisory committee vote counts and the internal review timeline reported in secondary sources have not been independently confirmed against FDA meeting minutes for this article and should be verified before being repeated as precise figures. Amgen resubmitted with additional analyses in 2018, a second advisory committee meeting favored approval with labeling restrictions, and the FDA approved the drug in April 2019 (FDA approval letter, 2019).

What the two pivotal trials showed

FRAME randomized postmenopausal women with osteoporosis to romosozumab or placebo for 12 months, with both groups transitioning to denosumab afterward. The trial is widely reported to have shown a large relative reduction in new vertebral fractures at 12 months and meaningful gains in lumbar spine and hip bone mineral density, exceeding what single agents typically produce over the same period. The specific percentage figures commonly cited for FRAME (fracture reduction and BMD change) originate from the published trial and should be checked against the primary paper before being used in patient-facing or regulatory-facing material, since this draft's source citations for those exact numbers could not be verified against the underlying record.

ARCH compared romosozumab to alendronate as an active comparator, again for 12 months before both groups moved to alendronate. Fracture outcomes favored romosozumab. The cardiovascular finding that drove the label change was a numerical imbalance in adjudicated major adverse cardiovascular events, more myocardial infarctions, and more cardiovascular deaths in the romosozumab arm than in the alendronate arm during the first year. Investigators and later commentary raised the possibility that alendronate itself may have some cardioprotective effect, which would make the imbalance partly a comparator effect rather than purely a romosozumab effect. This distinction is unresolved and is the reason the boxed warning uses cautious language about risk-benefit assessment rather than a flat prohibition outside the two-year MI/stroke window.

What the label actually restricts

The FDA label contraindicates romosozumab in patients with a myocardial infarction or stroke within the preceding year, and instructs prescribers to weigh benefit against risk in anyone with other cardiovascular risk factors, discontinuing the drug if a cardiovascular event occurs during treatment (Evenity prescribing information, accessdata.fda.gov, 2019). Treatment is capped at 12 monthly doses; the FDA did not approve retreatment courses, based on the observation that the bone-forming effect diminishes after the first year as sclerostin activity returns. The EMA's authorization, granted in December 2019, lists prior MI or stroke as an outright contraindication rather than boxed-warning language, a structural difference between the US and EU labels worth noting for readers comparing the two (EMA EPAR, Evenity).

What is established, what is plausible, and what is not established

Established: Romosozumab is FDA-approved only for postmenopausal women with osteoporosis at high fracture risk, dosed for a fixed 12-month course, with a boxed warning for cardiovascular events based on the ARCH comparator trial. It is contraindicated within 12 months of an MI or stroke.

Plausible but not settled: Whether the ARCH cardiovascular imbalance reflects a true drug effect, a cardioprotective effect of the alendronate comparator, or some combination of both. Whether real-world patient factors change the drug's benefit-risk balance in ways the trials did not test directly.

Not established in the US label: Use in men, use in glucocorticoid-induced osteoporosis, and retreatment beyond one 12-month course. None of these are FDA-approved indications; any use outside the approved population and regimen is off-label and should be discussed explicitly as such.

A factor generic approval-history pages tend to skip: response is not uniform

FRAME and ARCH established average effects across their trial populations, but they do not tell an individual patient how much bone density gain to expect. Emerging observational research suggests real-world modifiers change the picture. A single-center analysis found that diabetes status and prior antiresorptive treatment history influenced romosozumab's measured efficacy in practice, meaning patients who already took a bisphosphonate or denosumab before starting romosozumab may not see the same BMD trajectory as antiresorptive-naive patients (Romosozumab Efficacy in Osteoporosis: Influence of Diabetes and Previous Antiresorptive Therapy). Separately, a stratified real-world Japanese cohort analysis reported that the relationship between vitamin D status and BMD response depended on renal function and prior treatment history rather than following a single simple pattern (Context-Dependent Association Between Serum 25-Hydroxyvitamin D and Romosozumab BMD Response). These are observational, single-cohort findings, not trial-level or guideline-level evidence, and they have not changed the FDA label. They matter mainly as a caution against assuming trial-average fracture and BMD figures apply equally to every patient, particularly those with diabetes, renal impairment, or prior osteoporosis treatment.

A related 2026 analysis also found that BMD gains at 12 months did not uniformly track with clinical and psychosocial recovery measures in postmenopausal patients, a reminder that a density scan improving is not the same as a patient reporting better function or quality of life (Densitometric gains do not uniformly translate into clinical and psychosocial recovery). This is a single study and should be treated as hypothesis-generating rather than practice-changing.

A structured way to think through the cardiovascular tradeoff

This is not medical advice and does not replace an individualized risk assessment by a prescriber. It is a way to organize the questions the FDA label and the ARCH data actually raise, for a conversation between patient and clinician.

Step 1: Does the contraindication apply? If there has been a myocardial infarction or stroke within the past 12 months, romosozumab is contraindicated under the FDA label. Stop here and discuss alternative agents (bisphosphonates, denosumab, or other approved osteoporosis treatments) with the prescriber.

Step 2: Is fracture risk genuinely "high" or "very high"? Romosozumab's approval and most guideline positioning target patients with recent fragility fracture, very low T-scores, or high FRAX-estimated probability, not general postmenopausal osteoporosis. If fracture risk is moderate, an antiresorptive-first approach avoids the cardiovascular question entirely.

Step 3: What is the baseline cardiovascular risk profile? Standard ASCVD risk estimation, independent of the osteoporosis decision, should inform this conversation. A patient with multiple uncontrolled cardiovascular risk factors but no qualifying event in the past year is not automatically excluded by the label, but the label explicitly asks the prescriber to weigh benefit against risk in that scenario, which means the decision should be documented and revisited, not defaulted.

Step 4: What happens after the 12 doses? Because the FDA did not approve retreatment, the plan for what comes next (denosumab, a bisphosphonate, or another agent) should be decided before starting romosozumab, not after finishing it. Stopping without a follow-on antiresorptive is associated with rapid loss of the BMD gained, based on the biologic rationale for sequential therapy established in FRAME's design; the specific real-world persistence rates require verification before being cited as fixed statistics.

Step 5: What would trigger stopping mid-course? Any new myocardial infarction or stroke during treatment should prompt discontinuation per the label. Any new significant hypocalcemia should be corrected before continuing, and the label specifies correcting hypocalcemia before starting at all.

Exception worth flagging to a prescriber: patients with prior antiresorptive exposure or diabetes may have a different expected BMD response than the trial averages suggest, based on the observational research above, which is a reason to set expectations conservatively rather than promise trial-level gains.

Post-market surveillance and biosimilars

The FDA uses its Sentinel System, an active surveillance network built on electronic health record and claims data, to monitor drugs after approval, including cardiovascular outcomes for romosozumab (FDA Sentinel Initiative, fda.gov). As of this writing, no new boxed-warning-level safety communication beyond the original 2019 warning has been issued that this draft can confirm from the source material available; readers should check the current FDA label directly for any updates, since label revisions do occur without a separate public safety alert. No biosimilar romosozumab products have been reported as approved as of this writing; biologics exclusivity periods for this class typically run in the range of a decade or more from original approval, and manufacturing complexity for a monoclonal antibody makes early biosimilar entry unlikely, though this should be treated as a general expectation, not a confirmed timeline.

Cost and access

Romosozumab is administered by a clinician and billed under Medicare Part B's buy-and-bill model when given in a physician's office; commercial plans commonly require prior authorization documenting T-score, fracture history, and cardiovascular risk assessment. Specific wholesale price figures change over time and were not independently verified for this draft; readers should confirm current pricing and coverage terms with a pharmacy benefit or the prescriber's office rather than relying on a fixed dollar figure here.

When to seek urgent care

Anyone experiencing chest pain, sudden weakness or numbness, difficulty speaking, or other signs of heart attack or stroke during romosozumab treatment needs emergency evaluation, not a scheduled follow-up call. This is standard advice for the boxed warning's risk category and is not specific to any one patient's history.